To test novel combination therapies aiming at increasing responses rates to immune checkpoint inhibitors, Explicyte has optimized a range of syngeneic mouse tumor models treated with anti-CTLA-4 or anti-PD-1/PD-L1 monoclonal antibodies.
This PLOS ONE paper, co-authored by Alban Bessède, CSO of Explicyte, demonstrates that the expression of tryptophan-degrading enzyme IDO1 is not strictly associated with L-Kynurenine production in breast and colorectal cancer tissues.